Table 2 Summary of Immunohistochemistry results for E2F5 antibody tested on OEC
From: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer
Type of tissue | Number of cases | Number positive | Percentage positive |
|---|---|---|---|
Fimbrial/Paratubal/Paraovarian cyst | 6 | 0 | 0 |
Surface epithelium/inclusion cysts | 14 | 0 | 0 |
Endometriotic cyst | 4 | 0 | 0 |
Serous cystadenoma | 8 | 0 | 0 |
Mucinous cystadenoma | 5 | 0 | 0 |
Benign stromal tumour | 4 | 0 | 0 |
Dermoid tumour (mature) | 12 | 0 | 0 |
Total | 67 | 0 | 0 |
Early and late malignant cases | Â | Â | Â |
Serous borderline and malignant E6; L8 | 24 (4+20) | 11(2+9) | 45.8 |
Mucinous borderline and malignant E11; L1 | 13 (6+7) | 4(1+3) | 30.77 |
Endometroid borderline and malignant E7; L5 | 16 (2+14) | 8(1+7) | 50 |
Clear cell carcinoma E2; L1 | 4 | 0 | 0 |
Adenocarcinoma (not further specified) E2; L2 | 4 | 2 | 50 |
Mixed adenocarcinoma E3; L1 | 7 | 6 | 85.7 |
Total | 68 | 31 | 45.6 |